Orthopediatrics Corp (KIDS) Receives Consensus Rating of “Buy” from Analysts

Orthopediatrics Corp (NASDAQ:KIDS) has been assigned an average rating of “Buy” from the six ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $35.00.

KIDS has been the subject of several recent research reports. BTIG Research increased their price target on shares of Orthopediatrics to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, January 2nd. BidaskClub lowered shares of Orthopediatrics from a “buy” rating to a “hold” rating in a research report on Thursday, December 27th. Finally, Zacks Investment Research raised shares of Orthopediatrics from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Wednesday, October 10th.

Shares of KIDS opened at $34.04 on Friday. The stock has a market cap of $411.25 million, a PE ratio of -5.97 and a beta of 0.19. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.67 and a quick ratio of 3.23. Orthopediatrics has a 52 week low of $14.00 and a 52 week high of $39.81.

Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Wednesday, October 31st. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $15.82 million for the quarter, compared to analyst estimates of $15.19 million. Orthopediatrics had a negative net margin of 55.97% and a negative return on equity of 65.26%. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.70) EPS. Equities analysts predict that Orthopediatrics will post -0.95 EPS for the current year.

A number of large investors have recently bought and sold shares of KIDS. Indiana Trust & Investment Management CO acquired a new stake in shares of Orthopediatrics during the third quarter worth approximately $248,000. BlackRock Inc. increased its holdings in shares of Orthopediatrics by 74.9% during the second quarter. BlackRock Inc. now owns 341,196 shares of the company’s stock worth $9,090,000 after buying an additional 146,115 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of Orthopediatrics during the third quarter worth approximately $4,805,000. EAM Investors LLC increased its holdings in shares of Orthopediatrics by 118.8% during the third quarter. EAM Investors LLC now owns 68,217 shares of the company’s stock worth $2,499,000 after buying an additional 37,045 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Orthopediatrics by 20.5% during the third quarter. JPMorgan Chase & Co. now owns 70,225 shares of the company’s stock worth $2,573,000 after buying an additional 11,931 shares in the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Featured Story: Fiduciary

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply